Clinical Trials Logo

Calcinosis clinical trials

View clinical trials related to Calcinosis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06379295 Not yet recruiting - Clinical trials for Coronary Artery Disease

Coronary Artery Calcification Assessed on PET/CT

CALCOTEP
Start date: May 21, 2024
Phase:
Study type: Observational

Calcification artery calcium (CAC) scoring is a valuable tool for determining the risk of major adverse cardiac events. It was found that CAC can be quantitatively assessed, by manual scoring or using deep-learning, on low-dose non ECG-gated, contrast-enhanced or non-enhanced CT scans performed in association of PET acquisition, with a good agreement with standard scans. The purpose of this study is to determine the impact of a systematic coronary artery calcification evaluation in patients undergoing 18F-FDG PET/CT imaging to improve primary prevention of cardiovascular diseases. A visual CAC assessment will be made for each patient, dividing them into four groups: none, mild, moderate or heavy CAC. When possible, a CAC score will be computed. Each patient will complete a questionnaire to collect risk factors, history of cardiovascular diseases and medications.

NCT ID: NCT06217458 Not yet recruiting - DCIS Clinical Trials

The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS

CEMinDCIS
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The study hypothesis is that the rate of inadequate surgical margins after conservative breast surgery for DICS and the rate of reoperation (re-excision or/and mastectomy) is lower in the group of patients who underwent standard preoperative mammography and CEM to assess the extent of DICS, compared to the group of patients for whom the preoperative assessment of the extent of in situ breast cancer was not performed using one of the imaging techniques with contrast medium such as contrast mammography or magnetic resonance imaging.

NCT ID: NCT06155578 Not yet recruiting - Systemic Sclerosis Clinical Trials

Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis

Cal-23
Start date: January 2, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This prospective placebo-controlled trial will enroll 20 patients with SSc and at least one calcinotic lesion of the hands that is palpable on physical examination and measurable on hand radiographs. Each subject will undergo a screening evaluation 1 month before treatment with the study drug is initiated. Each subject will be instructed to blindly self-apply either topical 25% sodium metabisulfite or placebo cream twice daily. In-person follow-up evaluations will be performed after 4-months, with monthly telehealth follow-up visits to ensure adherence and arrange study drug refill deliveries.

NCT ID: NCT05875675 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

Effects of Pioglitazone in Calcific Aortic Valve Disease

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of pioglitazone compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.

NCT ID: NCT05870852 Not yet recruiting - Scleroderma Clinical Trials

Effectiveness of ESWT and PNF in Scleroderma With Calcinosis

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

Investigation of the effects of ESWT and PNF exercises added to ESWT on calcinosis in Ssc patients. Calcinosis cutis is a common, difficult-to-treat manifestation of systemic sclerosis associated with high morbidity. The aim of this study is to investigate the efficacy of ESWT therapy for calcinosis cutis in Ssc patients. The effects on grip strength, sleep, function and quality of life will be investigated.

NCT ID: NCT05861648 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

Folic Acid Supplementation in Calcific Aortic Valve Disease

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of folic acid compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.

NCT ID: NCT05050669 Not yet recruiting - Clinical trials for Generalized Arterial Calcification of Infancy

Natural History Study of ENPP1 Deficiency and and the Early-onset Form of ABCC6 Deficiency

Start date: January 2022
Phase:
Study type: Observational

The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency (including Generalized Arterial Calcification of Infancy Type 1 [GACI] and Autosomal Recessive Hypophosphatemic Rickets Type 2 [ARHR2]) and the early-onset form of ABCC6 Deficiency (Generalized Arterial Calcification of Infancy Type 2 [GACI-2]) longitudinally.

NCT ID: NCT04966416 Not yet recruiting - Systemic Sclerosis Clinical Trials

Calcinosis Reduction by Pyrophosphate in SSC

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory. We would like to test if orally administered pyrophosphate prevents calcinosis formation.

NCT ID: NCT04108806 Not yet recruiting - PAD Clinical Trials

Study of Peripheral Arterial Calcification

Start date: September 27, 2019
Phase: N/A
Study type: Interventional

Aim of the work : 1. Using different calcification scoring systems to investigate the association between arterial calcification and clinical outcome following endovascular therapy

NCT ID: NCT04066855 Not yet recruiting - Clinical trials for Chronic Kidney Failure

Sclerostin and Vascular Calcification in CKD and Renal Transplant

Start date: December 2019
Phase:
Study type: Observational

the aim of the research is to determine the degree of vascular calcification in chronic kidney disease and post-transplant and whether there is a correlation with the level of serum sclerostin.